Physician profile
Albert Earl Rivera
NPI 1366583882
$6,199.87
in general payments reported to CMS, 2019-2025
27 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $173 · 2021: $3,345 · 2022: $50.49 · 2023: $944 · 2024: $553 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,369.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $572.01 | 2019-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $514.48 | 2023 | |
| Abbvie INC. | $344.52 | 2019-2025 | Rinvoq, Botox, Skyrizi |
| Genzyme Corporation | $215.17 | 2020-2025 | |
| Kerecis Limited | $168.66 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Pfizer INC. | $128.76 | 2019-2023 | |
| Janssen Biotech, INC. | $113.13 | 2023-2025 | Tremfya |
| Amgen INC. | $104.32 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $75.92 | 2019-2024 | |
| Leo Pharma INC. | $65.39 | 2025 | Anzupgo, Adbry |
| Ucb, INC. | $57.98 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $56.69 | 2019-2023 | Taltz |
| Regeneron Healthcare Solutions, INC. | $54.43 | 2023-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $53.78 | 2024-2025 | Via Matrix, Novachor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $50.70 | 2020 | |
| Biofrontera INC. | $39.25 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $37.69 | 2019-2023 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.63 | 2019-2024 | Cabtreo |
| Dermavant Sciences, INC. | $26.13 | 2022-2023 | Vtama |
| Incyte Corporation | $23.26 | 2024 | Opzelura |
| Convatec INC. | $20.13 | 2025 | |
| Dusa Pharmaceuticals, INC. | $19.90 | 2019 | |
| Galderma Laboratories, L.P. | $17.87 | 2025 | Nemluvio |
| Verrica Pharmaceuticals INC. | $17.33 | 2023 | Ycanth |
| Arcutis Biotherapeutics, INC. | $13.51 | 2025 | Zoryve |
| Medimetriks Pharmaceuticals, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.